RB1 and large cell neuroendocrine carcinoma: The results, as shown in Fig. 2A, revealed high-frequency mutations in TP53 (LCNEC: 69%, cSCLC-LCNEC: 90%, and SCLC: 83%), LRP1B (LCNEC: 33%, cSCLC-LCNEC: 52%, and SCLC: 40%), RB1 (LCNEC: 21%, cSCLC-LCNEC: 43%, and SCLC: 53%), KMT2D (LCNEC: 29%, cSCLC-LCNEC: 29%, and SCLC: 27%), and NOTCH1 (LCNEC: 17%, cSCLC-LCNEC: 10%, and SCLC: 20%), consistent with previous studies [16–18].